|
Recent Developments |
|
16-JAN-19
Suven Life Sciences announces today that the grant of one product patent from Australia and one product patent from Singapore corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036.
28-DEC-18
Suven Life Sciences announces that the grant of one product patent from Brazil and one product patent from Eurasia corresponding to the New Chemical... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015 (12) | 31-Mar-2014 (12) | | Net sales | 4995.21 | 5208.55 | 5103.12 | | Other Income | 193.50 | 85.81 | 30.30 | | Total Income | 5188.71 | 5294.36 | 5133.42 | | Cost of goods sold | 3810.64 | 3517.58 | 2912.54 | | OPBDIT | 1378.07 | 1776.78 | 2220.88 | | PAT | 949.70 | 1087.50 | 1441.58 | | Gross Block | - | - | - | | Equity capital | 127.28 | 127.28 | 116.83 | | EPS (Rs.) | - | 9.04 | 12.34 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 7.91 - 35.72 | 1.78 - 6.76 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 26.6 | 33.6 | 43.3 | | Net margin (% of OI) | 18.3 | 20.5 | 28.1 |
|
|
Detailed Financials
|
|
|
|
|
